The Pluripotential Effects of Hypolipidemic Treatment for Polycystic Ovary Syndrome (PCOS): Dyslipidemia, Cardiovascular Risk Factors and Beyond

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|17|9|908-921

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.17, Iss.9, 2011-03, pp. : 908-921

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiovascular Risk in the Different Phenotypes of Polycystic Ovary Syndrome

By  

Current Pharmaceutical Design, Vol. 22, Iss. 36, 2016-10 ,pp. : 5547-5553

Bentham Science Publishers

Access to resources Recommend Favorite

Risk factors for the deterioration of glucose metabolism in polycystic ovary syndrome

By Wang Jim X   Norman Robert J  

Reproductive BioMedicine Online, Vol. 9, Iss. 2, 2004-08 ,pp. : 201-204

Reproductive Healthcare Ltd

Access to resources Recommend Favorite

Advances in the treatment of polycystic ovary syndrome

By Moghetti Paolo  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 9, 2001-09 ,pp. : 1631-1640

Informa Healthcare

Access to resources Recommend Favorite

Metformin in the Treatment of Polycystic Ovary Syndrome

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2121-2125

Bentham Science Publishers

Access to resources Recommend Favorite

The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS) – an extended critical analysis

By Geisthövel Franz   Rabe Thomas  

Reproductive BioMedicine Online, Vol. 14, Iss. 4, 2007-04 ,pp. : 522-535

Reproductive Healthcare Ltd

Access to resources Recommend Favorite